Pharma Bio Serv Stock Cash And Equivalents
| PBSV Stock | USD 0.50 0.05 9.09% |
Pharma Bio Serv fundamentals help investors to digest information that contributes to Pharma Bio's financial success or failures. It also enables traders to predict the movement of Pharma OTC Stock. The fundamental analysis module provides a way to measure Pharma Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharma Bio otc stock.
Pharma |
Pharma Bio Serv OTC Stock Cash And Equivalents Analysis
Pharma Bio's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Pharma Bio Cash And Equivalents | 14.24 M |
Most of Pharma Bio's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Bio Serv is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Pharma Bio Serv has 14.24 M in Cash And Equivalents. This is 98.27% lower than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.47% higher than that of the company.
Pharma Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Bio's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Pharma Bio could also be used in its relative valuation, which is a method of valuing Pharma Bio by comparing valuation metrics of similar companies.Pharma Bio is currently under evaluation in cash and equivalents category among its peers.
Pharma Fundamentals
| Return On Equity | 0.0568 | |||
| Return On Asset | 0.033 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 4.87 M | |||
| Shares Outstanding | 22.95 M | |||
| Shares Owned By Insiders | 64.53 % | |||
| Price To Earning | 10.00 X | |||
| Price To Book | 1.15 X | |||
| Price To Sales | 0.90 X | |||
| Revenue | 19.4 M | |||
| Gross Profit | 4.88 M | |||
| EBITDA | 1.23 M | |||
| Net Income | 1.01 M | |||
| Cash And Equivalents | 14.24 M | |||
| Cash Per Share | 0.62 X | |||
| Total Debt | 520.77 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 9.07 X | |||
| Book Value Per Share | 0.72 X | |||
| Cash Flow From Operations | 592.46 K | |||
| Earnings Per Share | 0.04 X | |||
| Target Price | 1.77 | |||
| Number Of Employees | 140 | |||
| Beta | 0.36 | |||
| Market Capitalization | 20.88 M | |||
| Total Asset | 20.65 M | |||
| Retained Earnings | 20.5 M | |||
| Working Capital | 20.6 M | |||
| Current Asset | 22.27 M | |||
| Current Liabilities | 1.67 M | |||
| Z Score | 24.0 | |||
| Annual Yield | 0.06 % | |||
| Net Asset | 20.65 M |
About Pharma Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Bio Serv's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Bio Serv based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pharma OTC Stock Analysis
When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.